IPHYF (Innate Pharma) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IPHYF Innate Pharma SA IPHYF
35 GF Score
Price $1.65
GF Value $0.14
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Innate Pharma Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Innate Pharma Quality Rank Related Terms

IPHYF
35GF Score
Innate Pharma SA IPHYF
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Innate Pharma (IPHYF) Overvalued in 2026?

Based on GuruFocus' analysis, Innate Pharma stock appears to be overvalued. The current stock price of $1.65 is trading 1078.6% above its estimated GF Value™ of $0.14. GuruFocus considers Innate Pharma to be Significantly Overvalued.

Key valuation signals for IPHYF:

  • Quality Rank:
  • GF Value™: $0.14 vs. price of $1.65 (1078.6% above fair value)
  • GF Score™: 35/100 with 7 warning signs

No single metric tells the full story. See the IPHYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Innate Pharma Business Description

Address 117, Avenue de Luminy, Marseille, FRA, 13009
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
35GF Score

Get the complete analysis for IPHYF

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.65
Price
$0.14
GF Value